Chih-Ming Ho, UCLA, USA
Presentation Title: Personalized Theranostics
Dr. Chih-Ming Ho graduated from Mechanical Engineering Department of National Taiwan University with B. S. After receiving his Ph.D. from Johns Hopkins University, He started his career at the University of Southern California. In 1991, he moved to the University of California, Los Angeles (UCLA) to lead the university’s establishment of the micro-electro-mechanical-system (MEMS) field, while serving as the founding Director of the Center for Micro Systems. He held the Ben Rich-Lockheed Martin Professor Chair until he retired in 2016, and currently is a UCLA Distinguished Research Professor. Dr. Ho was the Director of the NASA supported Institute for Cell Mimetic Space Exploration (CMISE) and the NIH supported Center for Cell Control (CCC). He served as UCLA Associate Vice Chancellor for Research from 2001 to 2005.
His research interests include phenotypic personalized medicine (PPM), micro/nano fluidics, molecular sensors and turbulence. He was ranked by ISI as one of the top 250 most cited researchers in all engineering categories (2001-2014). For realizing personalized medicine, he and his colleagues have discovered that the drug-dose inputs are correlated with the phenotypic outputs with a Phenotypic Response Surface (PRS) through artificial intelligence based analysis. AI-PRS platform dictates the composition and the ratio of a globally optimized drug combination. The optimized drug combination can realize unprecedented levels of adaptability for treating a specific patient, even if changes to the regimen and dose/drug optimization are needed in a continuous basis. AI-PRS is an indication agnostic and mechanism free platform technology, which has been successfully demonstrated in about 30 diseases for children and adults with 0 misses.
In 1997, Dr. Ho was inducted as a member of the National Academy of Engineering. In the next year, he was elected as an Academician of Academia Sinica. He has received a Doctor of Engineering Honoris Causa from Hong Kong University of Science and Technology and Dr. Ho holds ten honorary professorships, including the Einstein Professor from the Chinese Academy of Sciences. Dr. Ho was elected a Fellow of AAAS, APS, AIMBE, AIAA and 3M-Nano Society.
Uwe Marx, TissUse GmbH, Germany
Presentation Title: From Organ-on-a-Chip Tools Towards Patients on Chips – Enforcing a Paradigm Shift in Drug Development
Uwe Marx, CEO and Founder of TissUse GmbH, is a German physician and biotechnologist, and is one of the world’s leading researchers in the fields of organ-on-a-chip technology. Recently, Marx has been working together with other scientists to reproduce the human organism on a microfluidic chip at a scale of 1:100,000. He has 32 years of experience in human organ engineering and protein drug development. Dr. Marx published more than 60 peer-reviewed scientific papers, reviews and book chapters. He is an active member of the Working Group Cell Culture Technology of the German DECHEMA Society for Chemistry and Biotechnology since 28 years, for a number of years serving at its executive board. He organized various international scientific conferences on 3D Cell Culture, Tissue engineering, Regenerative Medicine and Membrane-based Bioreactor Technologies. Uwe Marx advised the German federal Ministry of Education and Technology on strategies to develop a innovation background for regenerative technologies in Germany. He served as an expert advisor for biotech start-up programs of the German government. Dr. Marx holds a membership of the German Society of Immunology and was granted numerous awards, among them the Best Article Award in Annual Journal ALTEX 2017 and the Dorothy Hegarty Award for Best Article in ATLA in 2012. He is an active member at the Board of Trustees of the German Fraunhofer Institute for Cell Therapy and Immunology in Leipzig, Germany. First approaches to emulate systemic human biology in hollow fiber bioreactors have been patented by Uwe Marx as early as in 1991 thus pioneering human multi-organ modelling in vitro. Since, he became an inventor in 28 patent families with over 140 granted patents. He actively promotes translation of inventions into health care products and services through company foundations. In the past, Dr. Marx served at the Supervisory boards of the German Biotechs Affimed Therapeutics AG, Novoplant GmbH and VITA 34 AG. The latter he co-founded in 1997. Currently, he is a member of the Supervisory board of the Berlin-based biotech company ProBioGen AG, which he founded in 1994.
Luke Lee UC Berkeley, USA
Presentation Title: Ultrafast Photonic PCR and Organoids on Chip
Prof. Luke P. Lee received both his BA in Biophysics and PhD in Applied Physics and Bioengineering from
UC Berkeley. He joined the faculty at the UC Berkeley in
1999 after more than a decade of industry experience. He became the Lester John and Lynne Dewar Lloyd
Distinguished Professor of Bioengineering in 2005. He served as the Chair Professor in Systems
Nanobiology at the ETH Zürich from 2006 to 2007. He
became Arnold and Barbara Silverman Distinguished
Professor at Berkeley in 2010 and was reappointed
again 2015. He is the Founding Director of the Biomedical Institute for Global Healthcare Research & Technology (BIGHEART), and served as a Tan Chin Tuan Centennial Professor and Associate President (International Research and Innovation) at the National University of Singapore from 2016 to 2018. He is a Fellow of the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering. His work at the interface of biological, physical, and engineering sciences for medicine has been recognized by many honors including the IEEE William J. Morlock Award, NSF Career Award, Fulbright Scholar Award, and the HoAm Prize. He has over 350 peer-reviewed publications and over 60 international patents filed. His current research interests are quantum biological electron transfers in living organisms, molecular diagnostics of neurodegenerative diseases and cancer, and in vitro neurogenesis using, with a focus both on studying fundamental quantum nanobiology and on solving ill-defined problems of global healthcare.
Dr. Johnsee Lee, PhD, MBA, Personal Genomics, Taiwan
Presentation Title: Enabling Clinical Precision Medicine by Optoelectronic Single-Molecule Sequencing
Dr. Johnsee Lee is the Chairman of Taiwan Biotech Industry Organization (Taiwan BIO), and Founder & CEO of two biotech companies, Personal Genomics, Inc. and Quark Biosciences, Inc. Prior to his current position, he served as the President of Industrial Technology Research Institute (ITRI), the Chairman of the Development Center for Biotechnology (DCB), and also as the Board Director of Taiwan Semiconductor Manufacturing Corp. (TSMC). Dr. Lee has played a key leadership role in the development of Taiwan’s world-class high-tech industries. He is also the Chairman of Taiwan Precision Medicine & Molecule Diagnostic Industry Association.
Dr. Lee received his PhD from the Illinois Institute of Technology, and an MBA from the University of Chicago. He is also a graduate of Harvard Business School’s Advanced Management Program. Dr. Lee is the founder and the first director of the Biomedical Engineering Laboratory at ITRI. Over the last 15 years, he has successfully facilitated the founding of more than 15 biotech and IT start-up companies.
Before joining ITRI, Dr. Lee held various technical and managerial positions at Argonne National Laboratory and at Johnson Matthey Inc. in the U.S.A. He was elected as the President of the Federation of Asian Chemical Societies in 1999. Dr. Lee has also served as the President of Taiwan Telecare Industry Association, and the President of Monte Jade Science & Technology Association in Taiwan.
Dr. Lee has published numerous journal papers and patents. He received many honors and awards including the National Engineering Medal, CIE Distinguished Achievement Award, the Innovation Leadership Award by Global Views, and the Excellence in Research & Innovation Award by Frost & Sullivan.
Tomokazu Matsue, Tohoku University, Japan
Presentation Title: Recent Progress of Nanoscale Eletrochemical Imaging
Dr. Tomokazu Matsue is currently Professor of Graduate School of Environmental Studies (GSES), Tohoku University. He received his Ph. D from Tohoku University in 1981. After working as a postdoctoral fellow at University of Wisconsin, an associate professor, he was promoted to a full professor of Graduate School of Engineering, Tohoku University in 1999 and moved to GSES in 2003 at the time of its foundation. During 2010-2017, he was also appointed as a Professor and Principal Investigator of WPI-AIMR, Tohoku University. He also served as the Special Adviser to the President of Tohoku University for long time. His research interests are in electrochemical imaging, biosensing and bioelectronic devices and systems, intelligent micro/nanoelectrochemical systems, characterization of energy-related materials. For the activity in research communities, he is now the Vice-President of the International Society of Electrochemistry (ISE) and the editor of Electrochimica Acta (since 2002). During 2014-2015, he served as the President of the Electrochemical Society of Japan. He is now engaged in a Director/Research Leader of Center of Innovation (COI) Tohoku Project and leads more than 150 researchers from several universities and industries. He has published more than 350 original papers and more than 100 reviews and books. He received many awards, including The Chemical Society of Japan Award for Creative Work (The Chemical Society of Japan) and Award for Creative Work (The Electrochemical Society of Japan).
Evi Lianidou, University of Athens, Greece
Presentation Title: CTC characterization and applications
Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Dr Lianidou has established a Molecular Diagnostics Laboratory focused on Liquid Biopsy at the Department of Chemistry since 1998 (http://en.actc-lab.chem.uoa.gr/). Her lab is specializing in the Analysis of Circulating Tumor Cells (ACTC), and has access to many patient samples through extensive clinical collaborations. Her main research interests are on the development and clinical evaluation of: a) single-plex and multiplex quantitative RT- qPCR assays for the detection and molecular characterization of CTCs, b) multiplex assays for gene expression in CTCs based on the liquid bead array, c) DNA methylation assays in CTCs and ctDNA, d) highly sensitive assays for mutation analysis in CTCs and in ctDNA, and e) evaluation of circulating miRNAs as tumor biomarkers in plasma. Dr. Lianidou has 115 publications (https://www.ncbi.nlm.nih.gov/pubmed/?term=lianidou) and has organized together with Prof K. Pantel four international meetings on liquid biopsy: a) the 7th International Symposium on Minimal Residual Disease in Athens, (http://ismrc2009.chem.uoa.gr) , b) the 1st “Advances in Circulating Tumor Cells: From Basic Research to Clinical Practice” (www.actc2012.org), c) the 2nd ACTC meeting, (October 8th-11th, 2014), in Crete, Greece (www.actc2014.org) and d) the 3rd ACTC meeting, (October 4th-7th, 2017), in Rhodes, Greece (www.actc2017.org). Prof Lianidou is PI in the European TRANSCAN group “CTC-SCAN” and in the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu) and serves on the Editorial Boards of many international journals including Clin Chemistry, Clin. Cancer Res, Breast Cancer Res, Cancer Res, Oncotarget, and many others. Dr. Lianidou is an elected member and Chair of the Committee for Clinical Molecular Biology Curriculum of the International Federation of Clinical Chemistry (IFCC), (http://www.ifcc.org/ifcc-education-division/emd- committees/c-cmbc/) and is coordinating the M.Sc. program of Clinical Chemistry, at the Department of Chemistry, University of Athens (http://en.clinical- chemistry.chem.uoa.gr/).